IQAI Stock Overview
IQ-AI Limited, through its subsidiaries, develops software applications for the healthcare industry in Jersey, the United Kingdom, and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
IQ-AI Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.015 |
| 52 Week High | UK£0.058 |
| 52 Week Low | UK£0.013 |
| Beta | 2.94 |
| 1 Month Change | 14.81% |
| 3 Month Change | -51.56% |
| 1 Year Change | -36.73% |
| 3 Year Change | -80.00% |
| 5 Year Change | 34.78% |
| Change since IPO | -57.24% |
Recent News & Updates
Shareholder Returns
| IQAI | GB Healthcare Services | GB Market | |
|---|---|---|---|
| 7D | 3.3% | 2.5% | 2.3% |
| 1Y | -36.7% | 64.1% | 0.6% |
Return vs Industry: IQAI underperformed the UK Healthcare Services industry which returned 59.4% over the past year.
Return vs Market: IQAI underperformed the UK Market which returned 0.3% over the past year.
Price Volatility
| IQAI volatility | |
|---|---|
| IQAI Average Weekly Movement | 13.4% |
| Healthcare Services Industry Average Movement | 8.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: IQAI's share price has been volatile over the past 3 months.
Volatility Over Time: IQAI's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 6 | Trevor Brown | www.imagingbiometrics.com/iq-ai-ltd |
IQ-AI Limited, through its subsidiaries, develops software applications for the healthcare industry in Jersey, the United Kingdom, and the United States. Its products include IB Clinic, a toolkit of post-processing software plug-ins for integrating into existing medical image visualization applications; IB Rad Tech, a workflow engine that processes customized workflows; IB Neuro, which analyzes MR data sets and generates parametric perfusion maps quantifying changes in contrast over time; and IB Delta Suite that performs a various fundamental radiology operations, including image co-registration, subtraction, class map generation, and export. The company also offers IB DCE, which analyzes conventional T1 weighted images and generates an array of relevant perfusion and permeability parameters; IB Diffusion that analyzes MR diffusion-weighted images and generates apparent diffusion coefficient, extrapolated b-value, IVIM, and other parameter maps; and IB StoneChecker, a medical software tool to aid clinical decision making by providing information about a patient’s kidney stone.
IQ-AI Limited Fundamentals Summary
| IQAI fundamental statistics | |
|---|---|
| Market cap | UK£3.44m |
| Earnings (TTM) | -UK£481.49k |
| Revenue (TTM) | UK£562.93k |
6.1x
P/S Ratio-7.1x
P/E RatioIs IQAI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IQAI income statement (TTM) | |
|---|---|
| Revenue | UK£562.93k |
| Cost of Revenue | UK£8.28k |
| Gross Profit | UK£554.65k |
| Other Expenses | UK£1.04m |
| Earnings | -UK£481.49k |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0022 |
| Gross Margin | 98.53% |
| Net Profit Margin | -85.53% |
| Debt/Equity Ratio | 0% |
How did IQAI perform over the long term?
See historical performance and comparison